{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-019579","form_type":"8-K","ticker":"XLO","cik":"0001840233","company_name":"Xilio Therapeutics, Inc.","filed_at":"2023-12-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.944819+00:00","generated_at":"2026-06-07T16:22:40.620133+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Xilio initiates Phase 1 combo trial of XTX101 with atezolizumab; reports updated monotherapy data with 33% DCR","bullets":["Initiated enrollment for Phase 1 dose escalation of XTX101 in combination with atezolizumab; RP2D for combo expected Q2 2024.","Updated monotherapy data at RP2D (150 mg Q6W) show 33% disease control rate in late-line/IO refractory patients; no discontinuations due to TRAE.","Confirmed partial response in PD-L1 negative NSCLC patient continued through 36 weeks with complete resolution of liver metastases.","Plans to initiate Phase 2 trial in MSS CRC in Q3 2024, subject to obtaining sufficient additional capital.","Preliminary PK demonstrates tumor-selective activation: 96% in melanoma, 73% in liver metastasis vs 13% peripheral activation."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-019579","json":"https://secwatch.observer/filing/0001558370-23-019579.json","markdown":"https://secwatch.observer/filing/0001558370-23-019579.md","text":"https://secwatch.observer/filing/0001558370-23-019579.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840233/000155837023019579/0001558370-23-019579-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840233/000155837023019579/xlo-20231207x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T16:22:40.620133+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}